Abu Dhabi will now offer a more targeted breast cancer treatment for patients in advanced stages and resistance to conventional hormone therapy, giving them renewed hope and a better quality of life.
Camizestrant will provide a more precise treatment for patients before clear signs of disease progression appear and help control the cancer for longer and delay its progression, a statement from the Abu Dhabi Media office outlined.
It is being administered for the first time in a female patient at the Burjeel Cancer Institute under the supervision of the Department of Health – Abu Dhabi (DoH), the statement said, adding that the patient was identified with ESR1 gene mutation following a circulating tumor DNA (ctDNA) blood test.
The approach is supported by findings from the global SERENA-6 clinical trial, which showed that switching patients with the mutation to Camizestrant reduced the risk of disease progression or death by 56 per cent, compared with continuing conventional endocrine therapy.
"This achievement is not simply about introducing a new drug; it represents the adoption of a comprehensive precision oncology model built on continuous molecular monitoring," said Prof Humaid Bin Harmal Al Shamsi, Chief Executive Officer of Burjeel Cancer Institute.
Under the supervision of the Department of Health – Abu Dhabi, Burjeel Cancer Institute has become the first centre in the world to administer Camizestrant, a next-generation therapy for advanced breast cancer, supporting earlier and more personalised treatment for patients. pic.twitter.com/SHMDi9XGhp
— مكتب أبوظبي الإعلامي (@ADMediaOffice) June 17, 2026
H.H. Sheikh Mohammed receives condolences on passing of Sheikh Ahmed
UAE welcomes US statement on Sudan peace efforts
UAE President and Rulers offer condolences to H.H. Sheikh Mohammed
UAE among global leaders in nuclear security progress
